Osteonecrosis of the jaws secondary to bisphosphonate therapy: A case series

Journal of Contemporary Dental Practice

Volumn 9, Issue 1, 2008, Pages 063-069

  Kumar, Satish K S ^a   Meru, Michael C ^b   Sedghizadeh, Parish P ^c,d,e,f  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b DDS Program

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d American Board of Oral and Maxillofacial Pathology ^*

^e USCSD

^f Cedars Sinai Hospital   (United States)

Author keywords

Bisphosphonates; BPs; Diphosphonates; Jaws; ONJ; Osteonecrosis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

AGED; ARTICLE; BONE NECROSIS; BREAST TUMOR; CASE REPORT; CHEMICALLY INDUCED DISORDER; DENTURE; FEMALE; HUMAN; JAW DISEASE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; OSTEOPOROSIS; PATHOPHYSIOLOGY; PROSTATE TUMOR; RADIOGRAPHY; TOOTH EXTRACTION;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; DENTURES; DIPHOSPHONATES; FEMALE; HUMANS; JAW DISEASES; MALE; MIDDLE AGED; MULTIPLE MYELOMA; OSTEONECROSIS; OSTEOPOROSIS; PROSTATIC NEOPLASMS; TOOTH EXTRACTION;

EID: 38049103388     PISSN: None     EISSN: 15263711     Source Type: Journal    
DOI: 10.5005/jcdp-9-1-63     Document Type: Article

References (34)

1. Epstein S. Update of current therapeutic options for the treatment of postmenopausal osteoporosis. Clin Ther 2006;28(2):151-73.
2. Yuen KK, Shelley M, Sze WM, Wilt T, Mason MD. BPs for advanced prostate cancer. Cochrane Database Syst Rev 2006(4):CD006250.
3. Djulbegovic B, Wheatley K, Ross J, Clark O, Bos G, Goldschmidt H, Cremer F, Alsina M, Glasmacher A. BPs in multiple myeloma. Cochrane Database Syst Rev 2002(3):CD003188.
4. Wong R, Wiffen PJ. BPs for the relief of pain secondary to bone metastases. Cochrane Database Syst Rev 2002(2):CD002068.
5. Homik JE, Cranney A, Shea B, Tugwell P, Wells G, Adachi JD, Suarez-Almazor ME. A metaanalysis on the use of BPs in corticosteroid induced osteoporosis. J Rheumatol 1999;26(5):1148-57.
6. Caraglia M, Santini D, Marra M, Vincenzi B, Tonini G, Budillon A. Emerging anti-cancer molecular mechanisms of amino BPs. Endocr Relat Cancer 2006;13(1):7-26.
7. Pavlakis N, Schmidt R, Stockler M. BPs for breast cancer. Cochrane Database Syst Rev 2005(3):CD003474.
8. Licata AA. Discovery, clinical development, and therapeutic uses of BPs. Ann Pharmacother 2005;39(4):668-77.
9. Papapoulos SE. BP actions: physical chemistry revisited. Bone 2006;38(5):613-6.
10. Guay DR. Ibandronate, an experimental intravenous BP for osteoporosis, bone metastases, and hypercalcemia of malignancy. Pharmacotherapy 2006;26(5):655-73.
11. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: BPs and osteonecrosis of the jaws. Ann Intern Med 2006;144(10):753-61.
12. Reid DM. Once-monthly dosing: an effective step forward. Bone 2006;38(4 Suppl 1):S18-22.
13. Grigg AP, Shuttleworth P, Reynolds J, Schwarer AP, Szer J, Bradstock K, Hui C, Herrmann R, Ebeling PR. Pamidronate reduces bone loss after allogeneic stem cell transplantation. J Clin Endocrinol Metab 2006;91(10):3835-43.
14. Dimitrakopoulos I, Magopoulos C, Karakasis D. BP-induced avascular osteonecrosis of the jaws: a clinical report of 11 cases. Int J Oral Maxillofac Surg 2006;35(7):588-93.
15. Kuehn BM. Reports of adverse events from bone drugs prompt caution. JAMA 2006;295(24):2833-6.
16. Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of BP-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007;65(3):415-23.
17. Bilezikian JP. Osteonecrosis of the jaw - do BPs pose a risk? 2006;355(22):2278-81.
18. Ruggiero SL, Fantasia J, Carlson E. BP-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;102(4):433-41.
19. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of BPs: a review of 63 cases. J Oral Maxillofac Surg 2004;62(5):527-34.
20. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006;296(24):2927-38.
21. Shanbhag AS. Use of BPs to improve the durability of total joint replacements. J Am Acad Orthop Surg 2006;14(4):215-25.
22. Van den Wyngaert T, Huizing MT, Vermorken JB. BPs and osteonecrosis of the jaw: cause and effect or a post hoc fallacy? Ann Oncol 2006;17(8):1197-204.
23. Marx RE, Sawatari Y, Fortin M, Broumand V. BP-induced exposed bone (osteonecrosis/ osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63(11):1567-75.
24. Suzuki K, Takeyama S, Sakai Y, Yamada S, Shinoda H. Current topics in pharmacological research on bone metabolism: inhibitory effects of BPs on the differentiation and activity of osteoclasts. J Pharmacol Sci 2006;100(3):189-94.
25. Polizzotto MN, Cousins V, Schwarer AP. BP-associated osteonecrosis of the auditory canal. Br J Haematol 2006;132(1):114.
26. Purcell PM, Boyd IW. BPs and osteonecrosis of the jaw. Med J Aust 2005;182(8):417-8.
27. Hellstein JW, Marek CL. BP osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century? J Oral Maxillofac Surg 2005;63(5):682-9.
28. Migliorati CA, Siegel MA, Elting LS. BP-associated osteonecrosis: a long-term complication of BP treatment. Lancet Oncol 2006;7(6):508-14.
29. Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65(3):369-76.
30. American Dental Association Council on Scientific Affairs. Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc 2006;137(8):1144-50.
31. Marx RE. Oral & Intravenous BP-Induced Osteonecrosis of the Jaws. Illinois: Quintessence Publishing Co, Inc; 2007.
32. Dannemann C, Gratz KW, Riener MO, Zwahlen RA. Jaw osteonecrosis related to bisphosphonate therapy: a severe secondary disorder. Bone 2007;40(4):828-34.
33. Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel, MA, Woo SB. Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc 2005;136(12):1658-68.
34. Carter G, Goss AN, Doecke C. Bisphosphonates and avascular necrosis of the jaw: a possible association. Med J Aust 2005;182(8):413-5.